Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been recommended as preventive therapies for patients with acute myocardial infarction (AMI) in the European Society of Cardiology and American College of Cardiology/American Heart Association (ACC/AHA) guidelines [1–3]. Here, ACE is linked to acute myocardial infarction.